The Week Ahead: COS...
Services: Diversified Services
Furiex Pharmaceuticals Inc. (FURX: NASDAQ)
$39.36 -0.50 | -1.25%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | ||
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -42.86M | -48.98M | -54.66M | |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | |
| (Increase) Decrease In Receivables | -9.76M | -1.73M | 302.00K | |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | |
| (Decrease) Increase In Payables | 6.51M | -3.00K | 21.00K | |
| (Decrease) Increase In Other Current Liabilities | -192.00K | -3.34M | 7.45M | |
| (Increase) Decrease In Other Working Capital | 154.00K | 40.00K | 149.00K | |
| Other Non-Cash Items | 5.54M | 4.18M | 1.21M | |
| Net Cash From Continuing Operations | -40.63M | -49.00M | -43.32M | |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -40.63M | -49.00M | -43.32M | |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | |
| Purchases of Property, Plant & Equipment | -77.00K | -22.00K | -683.00K | |
| Acquisitions | 0.00 | 0.00 | 3.46M | |
| Purchases of Short-Term Investments | -7.50M | -10.00M | 0.00 | |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 2.42M | -10.02M | 2.78M | |
| Issuance of Debt | 30.00M | 10.00M | 0.00 | |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 600.00K | 620.00K | 0.00 | |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | |
| Other Financing Charges, Net | -300.00K | 0.00 | 122.57M | |
| Net Cash From Financing Activities | 30.30M | 10.62M | 122.57M | |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | |
| Net Change in Cash & Cash Equivalents | -7.91M | -48.40M | 82.02M | |
Portfolios with FURX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- User0730
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
Latest FURX Headlines from TheStreet
- 4 Stocks Spiking on Unusual Volume 02.14.13 | 07:02 am
- These 10 ¿¿Buyâ¿ Rated Stocks Have Significant Insider Buying Activity 02.06.13 | 02:02 pm
- Stocks Mixed as Investors Take Breather 01.28.13 | 02:01 pm
- Stock Futures Rise After Caterpillar, Durable Goods Reports 01.28.13 | 09:01 am
- Furiex Pharmaceuticals Inc. Stock Upgraded (FURX) 11.27.12 | 04:11 am
- 7 Stocks Rising on Unusual Volume 07.30.12 | 02:07 pm
- Insiders Trading END, HUTC, FURX, SNI 06.18.12 | 10:06 am
- Insiders Trading HPQ, LNKD, FURX, CPRT 06.05.12 | 10:06 am
- Insiders Trading FURX, DSW, PMTI, CTL 06.01.12 | 01:06 pm
- Insiders Trading CVI, FB, FURX, BLK 05.25.12 | 09:05 am
Press Releases for FURX
- Furiex Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.06.13 | 04:03 pm
- Furiex Pharmaceuticals To Present At Cowen & Company 33rd Annual Healthcare Conference - Business Wire 02.26.13 | 09:02 am
- Furiex Receives Qualified Infectious Disease Product And Fast Track Designations From The U.S. Food And Drug Administration For Avarofloxacin (JNJ-Q2) - Business Wire 02.25.13 | 04:02 pm
- Furiex Pharmaceuticals Announces Fourth Quarter And Full Year 2012 Earnings Release And Conference Call - Business Wire 01.29.13 | 04:01 pm
- Furiex Confirms Takeda’s Receipt Of FDA Approval Of NESINA (alogliptin) And Fixed-Dose Combinations OSENI (alogliptin And Pioglitazone) And KAZANO (alogliptin And Metformin HCl) For The Treatment Of Type 2 Diabetes - Business Wire 01.25.13 | 07:01 pm
- Furiex Reports Third Quarter 2012 Financial Results - Business Wire 11.01.12 | 04:11 pm
- Furiex Pharmaceuticals Announces Third Quarter 2012 Earnings Release And Conference Call - Business Wire 10.01.12 | 04:10 pm
- Furiex Reports Second Quarter 2012 Financial Results - Business Wire 08.02.12 | 04:08 pm
- Furiex Pharmaceuticals Amends Current Loan And Security Agreement, Adding An Additional $30.0 Million - Business Wire 08.02.12 | 04:08 pm
- Furiex Pharmaceuticals Announces Closing Of Priligy® Asset Transfer And License Agreements - Business Wire 07.30.12 | 04:07 pm
Partner Headlines for FURX
- Furiex Pharmaceuticals: Here’s What Investors Need to Know Before Earnings - Wall St. Cheat Sheet 05.07.13 | 12:05 pm
- Furiex Pharmaceuticals Earnings: Here’s Why Investors are Not Happy Now - Wall St. Cheat Sheet 05.07.13 | 06:05 am
- 5 Pharmaceutical Companies With Insider Buying During August 14-16 - Seeking Alpha 08.19.12 | 05:08 am
- Insider Trades: Opportunity Or Sham? - Seeking Alpha 08.19.12 | 05:08 am
- Furiex Confirms Takeda's Resubmissions of Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone NDAs to FDA - Benzinga 07.27.12 | 04:07 pm
- Healthcare Business Rewind: Furiex' GOOD NEWS, Pfizer TERMINATES Licenses - Wall St. Cheat Sheet 07.27.12 | 06:07 am
- 3 Outperforming Small Caps Bought Up By Insiders And Hedge Funds - Seeking Alpha 04.13.12 | 07:04 pm
- Furiex Pharmaceutical's Coming Events Could Boost Stock Price - Seeking Alpha 03.26.12 | 09:03 am
- Insider Buys And Sells: Sohu, Tesla - Seeking Alpha 03.19.12 | 09:03 am
- Heavy Activity For Furiex Pharmaceuticals In 2012 - Seeking Alpha 01.23.12 | 08:01 am
